Iovance surges 19% on Amtagvi revenue beat, sarcoma breakthrough
Q4 sales of $87M exceed estimates as gross margin reaches 50%, while TIL therapy shows 50% response rate in rare cancers
Iovance Biotherapeutics shares surged 19% on Tuesday after the cancer immunotherapy company reported fourth-quarter revenue that beat analyst expectations, driven by accelerating demand for its newly launched melanoma treatment Amtagvi.
The San Carlos-based company posted Q4 2025 product revenue of $87 million, exceeding the $82 million consensus estimate and marking 30% sequential growth from the prior quarter. U.S. sales of Amtagvi, the first tumor-infiltrating lymphocyte (TIL) therapy approved by the Food and Drug Administration, reached approximately $65 million during the period, according to the company's earnings announcement.
The commercial momentum helped Iovance achieve full-year 2025 revenue of $264 million, meeting the company's guidance target. Perhaps more significantly for investors focused on the path to profitability, gross margin improved to 50% during the fourth quarter, up from prior periods as manufacturing scales and the company benefits from operational efficiencies.
"We are executing well against our commercialization and clinical development priorities," the company stated in its earnings release, highlighting progress across multiple therapeutic programs. The strong financial performance extends the company's cash runway into the third quarter of 2027, providing substantial flexibility to fund ongoing clinical trials and commercial expansion efforts.
Beyond the commercial progress, Iovance delivered two significant clinical catalysts that bolstered investor confidence. The U.S. FDA granted Fast Track designation for lifileucel, the company's investigational TIL therapy, for the treatment of non-small cell lung cancer (NSCLC). This designation is designed to expedite the review of drugs for serious conditions where there is significant unmet medical need, potentially accelerating the path to regulatory approval.
Separately, Iovance reported positive early data from a pilot clinical trial of lifileucel in patients with advanced soft tissue sarcomas. Among the first six evaluable patients treated with monotherapy, the physician-assessed confirmed objective response rate reached 50%—a striking result given that current second-line treatment options for these aggressive cancers typically achieve response rates of less than 5%.
These sarcomas, specifically undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, affect more than 8,000 patients annually in the United States and Europe. Building on these compelling results, Iovance plans to initiate a single-arm registrational trial in second-line advanced sarcoma patients during the second quarter of 2026, with the goal of pursuing accelerated FDA approval.
The company's loss per share for the quarter came in at $0.18, slightly wider than the $0.17 consensus forecast, reflecting continued investment in clinical development and commercial infrastructure. However, analysts have largely maintained positive ratings on the stock, with an average target price of $9.11—representing significant upside from Tuesday's trading levels around $3.44 per share.
Iovance's performance stands in contrast to broader biotechnology sector trends, where many clinical-stage companies have struggled to achieve commercial traction following product approvals. The 30% sequential revenue growth for Amtagvi suggests the company is successfully navigating the complex logistics of personalized cell therapy manufacturing while building market awareness among oncologists and patients.
The multiple catalysts announced Tuesday—commercial momentum, margin expansion, regulatory progress in lung cancer, and breakthrough data in sarcoma—position Iovance to advance its pipeline of TIL therapies across multiple tumor types. With cash secured through mid-2027 and several potential value-creating events on the horizon, investors will be closely watching the company's ability to maintain Amtagvi's growth trajectory while executing on the planned sarcoma registrational trial later this year.